MeiraGTx Holdings PLC MGTX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 21, 2025 (filed on Jan 21, 2025)

Insider Name:

Giroux Richard

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-24,000

Price:

$6.29
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Zeldin Robert K

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-37,500

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Zeldin Robert K

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-15,149

Price:

$5.77
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Zeldin Robert K

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

37,500

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Wollin Robert J

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-5,000

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Wollin Robert J

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,909

Price:

$5.77
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Wollin Robert J

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

5,000

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Naylor Stuart

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-23,750

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Naylor Stuart

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-11,163

Price:

$5.77
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Naylor Stuart

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

23,750

Price:

--

Filings by filing date

Jan 21, 2025 (filed on Jan 21, 2025)

Insider Name:

Giroux Richard

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-24,000

Price:

$6.29
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Zeldin Robert K

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-37,500

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Zeldin Robert K

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-15,149

Price:

$5.77
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Zeldin Robert K

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

37,500

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Wollin Robert J

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-5,000

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Wollin Robert J

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,909

Price:

$5.77
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Wollin Robert J

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

5,000

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Naylor Stuart

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-23,750

Price:

--
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Naylor Stuart

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-11,163

Price:

$5.77
Jan 14, 2025 (filed on Jan 16, 2025)

Insider Name:

Naylor Stuart

Ownership Type:

Direct Ownership

Securities:

Ordinary Shares

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

23,750

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	450 EAST 29TH STREET, 14TH FLOOR NEW YORK NY 10016
Tel:	N/A
Website:	https://meiragtx.com
IR:	See website

Key People

Alexandria Forbes President, Chief Executive Officer, Director	Richard Giroux Chief Financial Officer, Chief Operating Officer	Robert J. Wollin General Counsel, Secretary
Stuart Naylor Chief Development Officer	Robert K. Zeldin Chief Medical Officer

Business Overview

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren's Syndrome; AAV-GAD for the treatment of Parkinson's Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Financial Overview

For the nine months ended 30 September 2024, MeiraGTx Holdings PLC revenues decreased 1% to $11.9M. Net loss increased 4% to $108.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects License and collaboration segment loss increase from $61.5M to $132.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.90 to -$1.62.

Employees:	389 as of Sep 30, 2024

Reporting Currency:	U.S. Dollars
Enterprise value:	$424.46M as of Sep 30, 2024
Annual revenue (TTM):	$13.93M as of Sep 30, 2024
EBITDA (TTM):	-$162.81M as of Sep 30, 2024
Net annual income (TTM):	-$88.18M as of Sep 30, 2024
Free cash flow (TTM):	-$102.53M as of Sep 30, 2024
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	78,153,401 as of Oct 29, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization